Propanc Biopharma, Inc.
PPCBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePropanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in. With a market capitalization of $289K, it sits in micro-cap territory. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Market Cap
$289,271
Beta
3.33
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-176.20
EPS (Fwd)
—
ROE
-161.9%
ROA
-70.1%
Cash
$832,006
Total Debt
$509,116
Free CF
$1.7M
52W Change
-99.2%
Annual Financials
Cash vs Debt
Where PPCB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PPCB finished 80.37% below its 150-day moving average ($1.63) and 88.89% below its 200-day moving average ($2.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PPCB overbought or oversold?
At the October 20, 2026 close, PPCB's RSI(14) was 13.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $832K in cash comfortably exceeding the $509K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $1.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -161.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 3.33 means PPCB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. No single metric tells the full story. Reviewing PPCB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.